We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Nanoparticle-Encapsulated Leelamine Shown Safe for Treating Malignant Melanoma

By LabMedica International staff writers
Posted on 02 Nov 2014
Print article
Image: Leelamine is a natural compound isolated from pine bark (Photo courtesy of Pennsylvania State College of Medicine).
Image: Leelamine is a natural compound isolated from pine bark (Photo courtesy of Pennsylvania State College of Medicine).
Image: In preclinical animal studies, the Nanolipolee-007 nano-liposome drug was shown to be both safe and effective against malignant melanoma (Photo courtesy of Melanovus Oncology).
Image: In preclinical animal studies, the Nanolipolee-007 nano-liposome drug was shown to be both safe and effective against malignant melanoma (Photo courtesy of Melanovus Oncology).
Cancer researchers have packaged an effective but highly toxic cancer drug into a nano-liposome package that can be delivered to malignant melanoma cells with minimal damage to surrounding normal tissues.

The drug, leelamine, which is a natural compound isolated from pine bark, is a diterpene compound and a weak agonist of the cannabinoid CB1 receptor. Leelamine has been reported to inhibit PDK (pyruvate dehydrogenase kinase) activity.

The PI3 kinase (PI3K), MAP kinase (MAPK), and STAT3 molecular pathways promote disease development by being constitutively activated in 50%–70% of melanomas. In earlier studies leelamine inhibited the growth of preexisting xenografted melanoma tumors by an average of 60% by targeting the PI3K, MAPK, and STAT3 pathways without affecting animal body weight or blood markers of major organ function. The mechanism of action of leelamine was mediated by disruption of cholesterol transport, causing decreased cellular proliferation and, consequently leading to increased tumor cell apoptosis as well as decreased tumor vascularization.

Unfortunately, leelamine is not a suitable drug for use in humans due to its poor bioavailability and lethality when administered intravenously. To overcome these limitations, investigators at The Pennsylvania State University College of Medicine (Hershey, USA) developed a delivery system for leelamine based on nanoparticle-sized liposomes. The nano-liposomes (nicknamed Nanolipolee-007) could be loaded stably with leelamine up to 60% of their volume.

Results published in the October 2014 edition of the journal Molecular Cancer Therapeutics revealed that the Nanolipolee-007 nanoparticles were as effective at killing melanoma cells as leelamine dissolved in DMSO and were more effective at killing cultured melanoma compared with normal cells. Mechanistically, the Nanolipolee-007 particles acted in a fashion identical to natural leelamine by inhibiting PI3K/Akt, STAT3, and MAPK signaling mediated through inhibition of cholesterol transport.

Nanolipolee-007 inhibited the growth of preexisting xenografted melanoma tumors by an average of 64% by decreasing cellular proliferation, reducing tumor vascularization, and increasing cellular apoptosis, with negligible toxicity.

“The drug is packaged into a lipid ball significantly smaller than the width of a hair to make it soluble in the blood stream and prevent negative side effects. The drug-containing nanoparticle ball then travels in the bloodstream to the tumor, where it accumulates and the drug is released in the tumor to kill the cancer cells,” said senior author Dr. Gavin Robertson, professor of pharmacology, pathology, dermatology, and surgery at The Pennsylvania State University College of Medicine. “This nanoparticle moves leelamine one step closer to the clinic. We now have a drug that has the potential to be given to humans that could not be done before.”

Pennsylvania State University has patented this discovery and has licensed it to Melanovus Oncology (Jensen Beach, FL, USA) to conduct a series of FDA-required studies to enable clinical testing of the drug in humans.

Related Links:

The Pennsylvania State University College of Medicine
Melanovus Oncology


Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Unit-Dose Packaging solution
HLX
New
Adenovirus Detection Kit
REALQUALITY RQ-ADENO
New
CVD Risk Test
GammaCoeur CVD Risk ELISA Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: Schematic overview of maternal biomarker discovery using cell-free RNA during pregnancy (Photo courtesy of Circulation Research (2024). DOI: 10.1161/CIRCRESAHA.124.325024)

Maternal Blood Test Identifies Congenital Heart Diseases in Fetus

Each year, around 1,000 children are born with a single ventricle heart defect (SVHD), a condition where one of the heart's lower chambers is underdeveloped, too small, or missing a valve.... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.